Navigation Links
Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients
Date:11/4/2011

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

Nasopharyngeal carcinoma is endemic in Southern China and Southeast Asia, where radiotherapy (RT) has been the primary treatment. Although the National Comprehensive Cancer Network (NCCN) recommends concurrent chemo-radiotherapy (CCRT) for stage II disease, evidence regarding its efficacy is weak, and this has not been defined as a primary endpoint in phase III trials.

To determine whether or not combined chemotherapy and radiotherapy confers survival benefit to stage II NPC patients, Qui-Yan Chen, M.D., Ph.D., of the Sun Yat-sen University Cancer Center in the People's Republic of China, and colleagues, conducted a phase III trial of patients randomly assigned to receive either radiation therapy (114 patients) or combined chemotherapy and radiation (116 patients).

They also found that after a median follow-up of 60 months, 22.8% of patients in the radiation group had disease progression, compared to 11.2% in the concurrent therapy group. The researchers found that 5-year overall survival, progression-free survival, and distant metastasis-free survival were statistically significantly higher in the concurrent therapy group compared with the group receiving radiation alone.

The authors conclude that based on the results of this trial, which they believe to be the first phase III trial to compare CCRT and RT, the NCCN guidelines are reasonable. They hypothesize that early-stage disease may have a smaller distant tumor bulk, and thus CCRT may be more effective in eradicating distant micro-metastases. Although patients in the combined therapy group experienced more toxic side effects than patients who only received radiotherapy, the regimen was overall well tolerated when the chemotherapy drug dose was reduced.

Chen et al write, "In summary, we think that the optimal choice for early-stage NPC is cisplatin, at a weekly dose of 30 mg/m2, for both an optimal chemotherapy effect to eradicate small distant tumors and to ensure NPC patient compliance."


'/>"/>
Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. New study introduces the prospect for concurrent antiangiogenic/antitumorigenic therapy
2. Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer
3. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. Scientists identify microRNA as possible cause of chemotherapy resistance
6. Study evaluates costs and benefits of new chemotherapy drugs
7. Older Colon Cancer Patients Less Likely to Get Chemo
8. Are New Chemo Treatments Cost-Effective?
9. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
10. Researchers find new chemotherapy combination shows promise in endometrial cancer
11. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... CastCoverz!, America’s #1 trusted brand ... country's oldest waterproof cast protector . As the largest one-stop, orthopedic shop, ... of daily, night, weatherproof and waterproof covers for most orthopedic devices, including but ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... Cosmetic Town, ... website, cosmetictown.com . The forum section was recently revamped and upgraded to allow ... surgical techniques in use across the country. , According to the senior editor of ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... has been collaborating with doctors and hospitals to make transformative changes in how ... leading cell therapy minds this week in discussing breakthroughs in cellular medicine to ...
(Date:4/28/2016)... ... ... USA Medical Card reminds us that May is National Stroke Awareness Month. According to ... of death in the United States; someone has one every 40 seconds. Annually, almost ... 65 years old. A stroke is when blood flow to the brain is blocked ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... M.D. has been named a Top Doc in Physical Medicine and Rehabilitation by ... with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership across ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
Breaking Medicine Technology: